Kurnaz Dilek, Semerci Seda Yilmaz, Babayigit Aslan, Cebeci Burcu, Buyukkale Gokhan, Cetinkaya Merih
J Pediatr Pharmacol Ther. 2018 May-Jun;23(3):219-222. doi: 10.5863/1551-6776-23.3.219.
Pulmonary atelectasis leads to difficulties in weaning of the neonates from mechanical ventilation. The management of persistent atelectasis in neonates constitutes a common challenge for physicians. Several reports suggested Recombinant human DNase (rhDNase) as a beneficial therapy for neonates with persistent atelectasis by reducing mucous viscosity. No adverse effect associated with rhDNase treatment was reported in neonates. Herein, we report probable adverse reactions associated with rhDNase use in a preterm infant. Therefore, we suggest that clinicians must be aware of this reaction in neonates and should carefully follow up these infants for the development of adverse reactions. We think that more clinical experience and data are needed to define its tolerability and adverse effect profile in neonates.
肺不张会导致新生儿机械通气撤机困难。新生儿持续性肺不张的管理是医生面临的一个常见挑战。几份报告表明，重组人脱氧核糖核酸酶（rhDNase）可通过降低黏液粘度，作为治疗新生儿持续性肺不张的有益疗法。未报告rhDNase治疗在新生儿中产生的不良反应。在此，我们报告了一名早产儿使用rhDNase可能出现的不良反应。因此，我们建议临床医生必须意识到新生儿中的这种反应，并应仔细随访这些婴儿，以观察不良反应的发生情况。我们认为，需要更多的临床经验和数据来确定其在新生儿中的耐受性和不良反应情况。
